Express Pharma
APRIL 25, 2024
In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca /Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. billion in sales and 28 per cent of the market share.
European Pharmaceutical Review
MAY 4, 2023
Amivantamab was the first bispecific monoclonal antibody (BsMAb) approved in the EU to treat advanced NSCLC with EGFR exon 20 insertion mutations post chemotherapy. Global Bispecific Antibodies for Cancer Market 2023-2027. Personalized medicine at FDA. Internet] Personalized Medicine Coalition. cited 2023Apr. Available from: [link] 8.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
APRIL 25, 2023
Venus Remedies has secured marketing authorisation from the UK for Cisplatin, a chemotherapy drug used as a first-line treatment for advanced ovarian cancer, testicular cancer and bladder carcinoma. million by 2027 at a CAGR of 8.99 The global market size of Cisplatin was valued at $394.5
The Happy PharmD
SEPTEMBER 4, 2024
Did you know that the infusion pharmacy market is projected to reach $20 billion dollars by 2027? From chemotherapy to nutrition support and infectious disease treatments, infusion pharmacists play a vital role in delivering specialized care directly to patients. Many pharmacists wonder how this growth could impact their careers.
FDA Law Blog: Biosimilars
FEBRUARY 11, 2024
The regulated cannabis marketplace brings in billions of dollars in revenue into state and federal governments, with predictions that cannabis sales will exceed $53 billion by 2027. Studies have found that marijuana access has public health benefits by reducing the rates of opioid use and opioid deaths.
Expert insights. Personalized for you.
116 
Let's personalize your content